An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

A specific assay has been developed for a blood-borne non-A, non-B hepatitis (NANBH) virus in which a polypeptide synthesized in recombinant yeast clones of the hepatitis C virus (HCV) is used to capture circulating viral antibodies. HCV antibodies were detected in six of seven human sera that were shown previously to transmit NANBH to chimpanzees. Assays of ten blood transfusions in the United States that resulted in chronic NANBH revealed that there was at least one positive blood donor in nine of these cases and that all ten recipients seroconverted during their illnesses. About 80 percent of chronic, post-transfusion NANBH (PT-NANBH) patients from Italy and Japan had circulating HCV antibody; a much lower frequency (15 percent) was observed in acute, resolving infections. In addition, 58 percent of NANBH patients from the United States with no identifiable source of parenteral exposure to the virus were also positive for HCV antibody. These data indicate that HCV is a major cause of NANBH throughout the world.

[1]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[2]  K. Steimer,et al.  Recombinant polypeptide from the endonuclease region of the acquired immune deficiency syndrome retrovirus polymerase (pol) gene detects serum antibodies in most infected individuals , 1986, Journal of virology.

[3]  R. Purcell,et al.  Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. , 1986, Annals of internal medicine.

[4]  K. Steimer,et al.  Human Cu/Zn superoxide dismutase cDNA: isolation of clones synthesising high levels of active or inactive enzyme from an expression library. , 1985, Nucleic acids research.

[5]  R. Kahn,et al.  Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. , 1984, Annals of internal medicine.

[6]  W. Szmuness,et al.  Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. , 1984, The New England journal of medicine.

[7]  S. Hadler,et al.  Occurrence of hepatitis A, B, and non-A/non-B in the United States. CDC sentinel county hepatitis study I. , 1984, The American journal of medicine.

[8]  J. Triginer,et al.  Posttransfusion Hepatitis in Spain. A Prospective Study , 1983, Vox sanguinis.

[9]  W. Szmuness,et al.  Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. , 1982, The New England journal of medicine.

[10]  M. Alter,et al.  Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. , 1982, The Journal of infectious diseases.

[11]  R. Kahn,et al.  Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. , 1981, The New England journal of medicine.

[12]  R. Knodell,et al.  Etiological spectrum of post-transfusion hepatitis. , 1975, Gastroenterology.

[13]  R. Purcell,et al.  CLINICAL AND SEROLOGICAL ANALYSIS OF TRANSFUSION-ASSOCIATED HEPATITIS , 1975, The Lancet.

[14]  J. Shuster,et al.  High level expression of proinsulin in the yeast, Saccharomyces cerevisiae. , 1987, Gene.

[15]  W. Magdzik,et al.  [Viral hepatitis - 1981]. , 1983, Przeglad Epidemiologiczny.